Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer.
It appears that the best outcomes will be achieved from the sequential use of multiple agents.
Written by:
Chrvala CA. Are you the author?
Reference: P T. 2012 Aug;37(8):453-63.
PubMed Abstract
PMID: 23091338
